Skip to main content
HR 3134 118th Congress House Health Accounting and auditing Business ethics Business records Competition and antitrust Congressional oversight Digestive and metabolic diseases Government information and archives Health care costs and insurance Health care coverage and access Health information and medical records Health programs administration and funding Health technology, devices, supplies Indian social and development programs Inflation and prices Intergovernmental relations Licensing and registrations Manufacturing Minority health Performance measurement

Emergency Access to Insulin Act of 2023

Introduced: May 9, 2023 Introduced by: Craig, Angie Democratic · Minnesota See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 17, 2024
Referred to the Subcommittee on Health.
May 12, 2023
Referred to the Subcommittee on Health.
May 9, 2023
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 9, 2023
Introduced in House
 Plain-English summary Congressional Research Service

Emergency Access to Insulin Act of 2023

This bill reduces the marketing exclusivity period for biological drug products from 12 to 7 years and establishes policies and programs designed to increase access to prescription insulin.

Specifically, the bill requires the Department of Health and Human Services (HHS) to award grants to states to create insulin card programs, which provide uninsured or underinsured individuals with insulin at no cost for specified time periods. Payments for insulin prescriptions made through the program must count toward an underinsured individual’s health plan deductible or other out-of-pocket expenses required under the plan. Further, HHS must collect annual fees from insulin manufacturers, based on each manufacturer’s market share, equal to the total estimated expenditures under the insulin grants program.

Subject to certain exceptions, the bill also establishes an excise tax on insulin manufacturers when the price of an insulin product spikes. The tax amount is a specified percentage of the revenue a manufacturer received as a result of the price spike. The tax amount increases in tiers based on the percentage of the price spike for that product.

What's happening now December 17, 2024

Referred to the Subcommittee on Health.

 Committees of jurisdiction 4